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Decreased cognitive ability is a significant problem in schizophrenia, and it has been pro-
posed that augmentation of antipsychotics with 5HT1A receptor agonists may improve
cognitive performance. Clinical studies have been mixed but there have been no stud-
ies specifically examining the effects of combining the atypical antipsychotic quetiapine
with the 5HT1A receptor partial agonist, buspirone on monoamine release. This is of inter-
est given previous evidence that monoamine release can alter cognition in schizophrenia.
In the present study we measured in vivo levels of monoamines in the frontal cortex
of Sprague Dawley rats and examined if buspirone (2.5 mg/kg i.p.), altered monoamine
release both when given alone and when combined with quetiapine (10 mg/kg i.p.). We
found that serotonin levels were not altered by either drug, either alone or in combination.
In contrast, both buspirone and quetiapine monotherapy significantly increased release
of noradrenaline (112 and 160% respectively) and dopamine (169 and 191% respectively)
compared to controls. However, there were no additional increases in in vivo monoamine
release when the combination of these drugs were given. One possible explanation for
these negative findings could be that the intrinsic 5HT1A agonist activity of quetiapine on its
own is of such significance that it is not further enhanced by buspirone. These findings do
not support clinical studies combining buspirone and quetiapine, if these were to be used
on the basis of enhanced monoamine neurotransmission. These findings may also have
implications for the atypical antipsychotic drugs in development which combine dopamine
D2 antagonism with 5HT1A partial agonism.
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INTRODUCTION
In schizophrenia clinically significant deficits in cognitive func-
tioning occur frequently, with meta-analyses suggesting that cog-
nitive functioning is reduced by between 0.5 and 1.5 SD below nor-
mal levels (Aleman et al., 1999; Johnson-Selfridge and Zalewski,
2001; Lee and Park, 2005). Treatment with atypical antipsychotics
can alleviate this to some degree (Meltzer and McGurk, 1999;
McGurk et al., 2005). It is likely that some atypical antipsychotics
improve cognition more than others, with quetiapine being among
the most effective (Riedel et al., 2007, 2010; Guo et al., 2011). Drugs
such as asenapine are hypothesized to improve cognitive perfor-
mance in primate studies due to effects on serotonin and dopamine
turnover (Elsworth et al., 2012).
Another suggestion for the cognitive improvement seen in
patients following administration of atypical antipsychotics is that
it may be due to agonist actions at the 5HT1A receptor (Meltzer and
Sumiyoshi, 2008; Depoortère et al., 2010), possibly by addressing
an underlying decrease in 5HT1A receptor stimulation (Sumiyoshi
et al., 1996). This suggestion is supported by findings that stim-
ulation of 5HT1A receptors results in an increase in extracellular
dopamine release in the prefrontal cortex (Yatham et al., 2005).
Interestingly, quetiapine is a partial agonist at the 5HT1A receptor
in prefrontal cortex, while having minimal affinity for these recep-
tors in the nucleus accumbens (Ichikawa et al., 2002; Yatham et al.,
2005).
To further examine this hypothesis, studies have examined
the effects on cognitive performance in schizophrenic patients of
adding 5HT1A receptor partial agonists to antipsychotics. The first
study examined the effects of adding tandospirone,a 5HT1A partial
agonist to ongoing treatment with typical antipsychotic drugs, and
reported some improvements in cognitive functioning (Sumiyoshi
et al., 2000, 2001). In another study by the same group some
modest cognitive benefits were found in one study combining the
5HT1A receptor partial agonist, buspirone, with atypical antipsy-
chotics (Sumiyoshi et al., 2007), but not in another smaller study
by another group (Piškulic et al., 2009). A more recent placebo-
controlled study in 46 schizophrenic patients found that addition
of buspirone significantly improved negative symptoms over an 8-
week study period (Ghaleiha et al., 2010). Thus, there appears some
clinical data to warrant further exploration of the clinical benefits
of adding 5HT1A receptor partial agonist, buspirone, to atypical
antipsychotics. Nonetheless, there appears little understanding of
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possible mechanisms of such a clinical benefit. Furthermore, to
date there have been no studies which have specifically focused
upon the combination of buspirone with quetiapine. This may
appear a logical choice for a study given the positive benefit of
quetiapine on cognitive functioning (Riedel et al., 2007, 2010; Guo
et al., 2011).
It is conceivable that any cognitive benefits arising from the
addition of 5HT1A receptor agonists are mediated via alterations
in monoamine release. Supporting this suggestion is increasing
evidence from animal models of cognitive changes in schizophre-
nia, which find alterations in monoamine release (McLean et al.,
2009; Depoortère et al., 2010; Meltzer et al., 2011; Elsworth et al.,
2012). Buspirone has also been shown in in vivo animal studies to
alter monoamine release, where it has been found to increase the
release of both noradrenaline (NA; Dalley et al., 1996; Gobert et al.,
1999) and dopamine (Gobert et al., 1999). Therefore, we wished to
determine if a combination of buspirone and quetiapine led to any
synergistic increases in the release of any of these monoamines. If
so, these findings might, in part, provide the rationale for a clinical
trial of this combination and, in part, help explain some of the
positive benefits seen in other clinical studies.
MATERIALS AND METHODS
All procedures on animals were approved by the University of
Alberta Health Sciences Animal Policy and Welfare Committee,
protocol number 456/07/07D and conducted according to CCAC
guidelines. The methods are very similar to those we have used in
other microdialysis studies (Hudson et al., 2012).
ANIMALS AND LABORATORY
The experiments were performed using male Sprague Dawley rats
(final weight, 270–300 g, obtained from Bioscience, University of
Alberta, Canada). Animals were held in a temperature – controlled
environment (23˚C) on a 12-h light/dark cycle with free access to
food and water. Animals were acclimatized to their environment
for 7 days prior to surgery.
DRUGS
Buspirone hydrochloride (2.5 mg/kg i.p.) and quetiapine fumarate
(10 mg/kg i.p.) were purchased from commercial sources (Sigma).
STEREOTAXIC SURGERY
Rats were anesthetized with chloral hydrate (400 mg/kg i.p. Sigma)
and placed in a stereotaxic frame. An incision was made in the
scalp to expose the cranium and a small 1 mm hole was bored
through the skull. The dura was broken and microdialysis probes
were located in frontal cortex (1.2 mm lateral, 2.7 mm anterior rel-
ative to bregma and to a depth of 5.0 mm relative to dura) using
a brain atlas for coordinates. Animals remained under anesthesia
for the duration of the experiment with additional chloral hydrate
administered as required. Core body temperature of each rat was
maintained at 37˚C with a homeothermic blanket and rectal ther-
mometer (Harvard, UK). Procedures were approved by Health
Sciences Animal Policy and Welfare Committee and conformed to
the guidelines set by the Canadian Council on Animal Care for
ethical experiments on laboratory animals.
MICRODIALYSIS: THE PROBES AND HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY
Concentric dialysis probes were constructed in-house, using stain-
less steel tubing (23 gage) with a 4 mm polyacrylonitrile mem-
brane length (ID: 0.2 mm; OD: 0.3 mm) and cut off MW 40,000
probes with a silica tubing outlet (OD: 0.17 mm). Once implanted
probes were perfused with artificial cerebrospinal fluid contain-
ing: 147 mM NaCl, 1 mM MgCl2, 1.3 mM CaCl2, and 3 mM KCl,
at a flow rate of 2µL/min using a syringe infusion pump (Harvard
Apparatus). Dialyzate samples were collected at 20 min intervals
in and immediately subject to analysis for monoamine content.
Extracellular monoamine levels were taken to be stable when three
consecutive samples values did not differ by 5% of one another.
The content of monoamines in dialyzate samples were quantified
using two independent high performance liquid chromatogra-
phy (HPLC) systems (one system for NA and one for DA and
5-HT), coupled with electrochemical detection (ECD), optimized
to detect monoamines and their metabolites separately. Briefly,
for NA assay mobile phase A containing 2 g/L sodium acetate,
3.1 g/L citric acid, 500 mg/L octanesulfonic acid, and 70 mg/L eth-
ylenediaminetetraacetic acid was dissolved in deionized water to
which methanol (13% v/v) was added (adjusted to pH 5.0 with
10 M NaOH). Mobile phase A was delivered at a flow rate of
1.1 ml/min onto a reverse analytical column (Hichrom, ODS 3µm
of 12.5 cm length ad 4.6 mm i.d.). Extracellular NA concentra-
tion was detected using a dual 5014A electrode cell paired to
a Coulochem II (ESA) electrochemical detector. First electrode
potential was set at −100 mV whilst the second electrode was
maintained at +250 mV. The retention time of NA was 5.5 min.
For the DA and 5-HT assay mobile phase B comprised of 10.92 g/L
sodium dihydrogen orthophosphate and 270 mg/L octanesulfonic
acid dissolved in deionized water to which methanol (14% v/v) was
added. Mobile phase B was delivered at a flow rate of 1.0 ml/min
onto a reverse phase analytical column (Beckman, ODS 3µm of
7.5 cm length and 4.6 mm i.d.). Extracellular levels of DA and 5-
HT were similarly measured; the second electrode potential was
set at +300 mV. The retention times of DA and 5-HT were 5.75
and 17 min respectively. The concentrations of the monoamines in
a given sample were determined by interpolating the peak height
obtained from standard curves.
Following implantation of dialysis probes stable baseline mea-
sures of the monoamines were established and then drugs or vehi-
cle injected (volume 1 ml/kg) at time zero. The doses of drugs were
chosen as those previously shown not to cause a maximal effect
on extracellular monoamines. The effects of the treatments were
monitored for 3 h and the animals euthanized by i.p. injection of
euthanyl (pentobarbitone 240 mg/ml;Vetoquinol,Canada). Brains
were then removed, frozen, sectioned and probe placement con-
firmed and only those animals that had correct placement of the
probes were included in the study.
STATISTICAL ANALYSIS
Data were analyzed by one-way repeated measures ANOVA fol-
lowed by Dunnett’s multiple comparison test for post hoc deter-
mination of significant differences from saline vehicle animals
following drug administration, then analyzed for significant dif-
ferences between treatment groups using Bonferroni’s test. This
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was done to allow appropriate testing for each part of the study
as Bonferroni’s test is used to compare selected pairs of results
(which have been pre-defined) while Dunnett’s is used to com-
pare all results to a control result. The level of significance was set
at p< 0.05. The results are reported as percentage of baseline.
RESULTS
EFFECTS ON SEROTONIN RELEASE
Neither buspirone alone nor quetiapine alone had any significant
effect on extracellular serotonin levels (Figure 1) compared to
saline controls. As with previous studies (Hudson et al., 2012),
serotonin levels decreased over time in control groups. Adminis-
tration of the combination of buspirone and quetiapine did not
significantly alter serotonin levels compared to either saline treated
controls or to either drug given alone (Figure 1).
EFFECTS ON NORADRENALINE RELEASE
Following administration of buspirone alone there was a signif-
icant elevation of extracellular NA relative to control animals
from 80 min onward (Dunnett’s Multiple Comparison Test 21.5,
p< 0.05), as shown in Figure 2. At 180 min the mean level of NA
release was 139% of baseline compared to 95% of baseline for the
saline controls. Administration of quetiapine alone resulted in a
significant elevation of NA compared to saline controls (Dunnett’s
Multiple Comparison Test 46.1, p< 0.001; Figure 2). Quetiapine
alone also led to significantly greater NA levels than buspirone
alone (Dunnett’s Multiple Comparison Test 24.6, p< 0.05). The
combination of buspirone and quetiapine did not significantly
alter levels compared to either buspirone alone (Bonferroni’s
Multiple Comparison Test 10.5, p> 0.05) or quetiapine alone
(Bonferroni’s Multiple Comparison Test 14.1, p> 0.05).
EFFECTS ON DOPAMINE RELEASE
Administration of buspirone alone caused a significant increase
in the levels of extracellular dopamine (Dunnett’s Multiple Com-
parison Test 47.25, p< 0.001), an effect that lasted until the end
of the experiment (Figure 3) at which point dopamine levels were
FIGURE 1 |The effect of Buspirone (2.5mg/kg i.p.) alone (n=7),
Quetiapine (10mg/kg i.p.) alone (n=7), the combination of these two
drugs (Busp/Quetcombi; n=7), and saline vehicle control (saline;
n=9) on extracellular levels ofof serotonin in rat frontal cortex. Drugs
were administered at time zero, values are means±SEM. There were no
statistically significant differences between any of the four groups.
164% of baseline compared to 87% of baseline in animals who
received saline. Administration of quetiapine resulted in a some-
what higher elevation of dopamine levels which was also highly
significant compared to saline controls (Dunnett’s Multiple Com-
parison Test 56.2, p< 0.001), an effect that also persisted until
the end of the experiment where dopamine levels were 180% of
baseline (Figure 3). However, there were no statistically significant
differences between the buspirone group and the quetiapine group
(Bonferroni’s Multiple Comparison Test 8.94,p> 0.05). The com-
bination of buspirone and quetiapine did not significantly alter
levels compared to either buspirone alone (Bonferroni’s Multiple
Comparison Test 15.5, p> 0.05) or quetiapine alone (Bonferroni’s
Multiple Comparison Test 6.6, p> 0.05).
FIGURE 2 |The effect of Buspirone (2.5mg/kg i.p.) alone (n=7),
Quetiapine (10mg/kg i.p.) alone (n=7), the combination of these two
drugs (Busp/Quetcombi; n= 7), and saline vehicle control (saline;
n=9) on extracellular levels of noradrenaline in rat frontal cortex.
Drugs were administered at time zero, values are means± sem. Both the
buspirone alone and quetiapine alone groups were statistically different
from saline controls. However, there were no statistically significantly
differences between the combination of buspirone and quetiapine from
either drug when given alone.
FIGURE 3 |The effect of Buspirone (2.5mg/kg i.p.) alone (n=7),
Quetiapine (10mg/kg i.p.) alone (n=7), the combination of these two
drugs (Busp/Quetcombi; n= 7), and saline vehicle control (saline;
n=9) on extracellular levels of dopamine in rat frontal cortex. Drugs
were administered at time zero, values are means± sem. Both the
buspirone alone and quetiapine alone group were statistically different from
saline controls. However, there were no statistically significantly differences
between the combination of buspirone and quetiapine from either drug
when given alone.
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DISCUSSION
The findings from the present study found that neither buspirone
or quetiapine, either alone or in combination, increased serotonin
release. These findings are consistent with previous studies, using
doses very similar to those examined previously (Routledge et al.,
1993; Gobert et al., 1999; Yamamura et al., 2009).
In the present study we found that buspirone monotherapy
increased NA release in rat frontal cortex. This is consistent with
several previous in vivo studies which have found that buspirone
reproducibly increases NA release (Dalley et al., 1996; Gobert
et al., 1999), as well as reversing the locus coeruleus inhibitory
effects of clonidine (Astier et al., 2003). It has been suggested
that this increase is due the active metabolite of buspirone,
1-(2-pyrimidinyl-piperazine) which acts as an a2-adrenoceptor
antagonist (Gobert et al., 1999). Additionally, buspirone increased
dopamine release, which has also been reported in previous studies
(Gobert et al., 1999).
In the present study we found that quetiapine significantly
increased the release of both NA and dopamine, which are again
consistent with the results from previous studies (Pira et al., 2004;
Yamamura et al., 2009).
There have been no previous studies, however, which have
examined the effects of a combination of buspirone and quetiapine
on monoamine levels. The findings from the present study found
no increase in the levels of any monoamine when these drugs were
combined. Interestingly, there has been one small 6-week placebo-
controlled study (n= 18) which examined the potential benefits
of augmenting a variety of atypical antipsychotics with buspirone
compared to placebo (Piškulic et al., 2009). For the study as a
whole there were no clinical effects of the addition of buspirone
on cognitive functioning compared to the placebo group. Of the
18 study patients, 4 were on quetiapine, all of whom were random-
ized to receive buspirone and not placebo. However, the results for
this subgroup were not reported so it cannot be certain that this
small subgroup did not have a different response. We are not aware
of any other clinical studies of this combination.
One possible explanation for the negative results would be
that both buspirone and quetiapine are acting via similar mech-
anisms, at least in part, to increase the release of both NA and
dopamine. Supporting this proposal are findings that quetiap-
ine is itself a partial agonist on 5HT1A receptors (Pisu et al.,
2010). Such a finding would also be compatible with the the-
ory that 5HT1A receptor partial agonism is an important con-
tributor to improve cognitive performance (Meltzer and Huang,
2008). This hypothesis is likely to be examined in more detail
since there are a number of novel atypical antipsychotic drugs
in development which combine dopamine D2 antagonism with
5HT1A partial agonism (Sumiyoshi et al., 2008; Newman-Tancredi,
2010; Meltzer et al., 2011). It will be of interest to see if these
drugs offer enhanced effects on cognition compared to existing
antipsychotics.
Should the results of the present study have been positive two
further sets of research would have been justified. The first would
have been to examine other antipsychotics in this model, partic-
ularly those which did not have activities at the 5HT1A receptor.
This would have clarified the potential role of this in the release of
monoamines. Secondly, it would have been important to examine
potential behavioral changes in non-anesthetized animals, partic-
ularly focusing on models that allow some possible measurement
of cognitive performance. Human volunteer studies of the com-
bination of these drugs on cognitive performance may also have
been warranted. However, given the negative findings from the
present study these additional studies were not carried out.
In conclusion, this study found no evidence for a synergis-
tic effect for buspirone and quetiapine on monoamine release. It
is possible these findings may be due to intrinsic 5HT1A recep-
tor partial agonism by quetiapine. However, the results of the
present study do not support clinical studies in which these
drugs are combined. These results also imply that any cognitive
benefits that occur clinically from combining atypical antipsy-
chotics and buspirone may not be due to increased release of
monoamines.
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